NVO

Novo Nordisk AS

38.15 USD

Last updated Oct 9, 05:01 UTC

Yesterday HIGH

$38.47

Yesterday LOW

$37.51

52w HIGH

$64.16

52w LOW

$35.12

EPS

0.96

PE

39.70

Next Earnings

Nov 4, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Novo Nordisk AS stock is down -14.39% since 30 days ago. The next earnings date is Nov 4, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 47.83% of the previous 45 October’s closed higher than September. In the last 10 Unusual Options Trades, there were 7 PUTs, 3 CALLs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

08 Oct 15:56	21 Jan, 2028	40.00	PUT	35	7783
08 Oct 16:01	21 Jan, 2028	65.00	PUT	15	325
08 Oct 16:34	17 Sep, 2027	37.50	PUT	63	1912
08 Oct 16:48	17 Dec, 2027	40.00	CALL	50	3445
08 Oct 16:57	15 Jan, 2027	37.50	CALL	180	1364
08 Oct 17:00	16 Oct, 2026	42.50	PUT	149	10464
08 Oct 17:00	20 Nov, 2026	42.50	PUT	149	4560
08 Oct 17:43	21 Jan, 2028	32.50	PUT	2000	1134
08 Oct 17:58	21 Jan, 2028	47.50	CALL	1000	573
08 Oct 19:12	18 Dec, 2026	50.00	PUT	21	4810

Advanced Data Unlock

Benzinga Newsdesk

Wed Sep 23, 2026

'Ozempic Maker Novo Open to Upgrading New York Listing' - FT

https://www.ft.com/content/00d53ca3-725f-4fa8-b452-cef562a13514?syn-25a6b1a6=1
Benzinga Insights

Tue Sep 22, 2026

3 Health Care Stocks With Whale Alerts In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Vandana Singh

Tue Sep 22, 2026

Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer

Public Citizen exposes separate government drug deals with Pfizer and Eli Lilly, warning the pacts could increase global drug prices.
Benzinga Newsdesk

Tue Sep 22, 2026

Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735, A Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors; 22% Placebo-Adjusted Weight Loss Reported At Week 33 Following Weekly Dosing Of VK2735At 17.5 MG; No Plateau Observed

Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to TreatmentUp to 97% of Weight Loss Maintained Following Transition to Every
Benzinga Insights

Mon Sep 21, 2026

10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Avi Kapoor

Mon Sep 21, 2026

Crude Oil Down 4%; Intel Shares Move Higher

U.S. stocks climbed Monday, led by Nasdaq (+1.77%) and Intel (+10%); communication shares rallied, while energy and oil fell.
Benzinga Newsdesk

Mon Sep 21, 2026

At Novo Nordisk Capital Markets Day, Co. CEO Says I Would Not Rule Out Acquiring Products Or Assets Which Are Already On The Market; Financial Impact From Compounders Has Gotten Less And Less

https://edge.media-server.com/mmc/p/xdjeyf7u/
Benzinga Newsdesk

Mon Sep 21, 2026

At Novo Nordisk Capital Markets Day, Co CFO Says Reasonable To Expect That We Should Be Able To Grow The Company By Mid-Single Digits Compound Annual Growth Rate Toward 2030

https://edge.media-server.com/mmc/p/xdjeyf7u/
Benzinga Newsdesk

Mon Sep 21, 2026

At Novo Nordisk Capital Markets Day, Co CFO Says Aim To Maintain Broadly Stable Operating Margin Until 2030 Compared To Today

https://edge.media-server.com/mmc/p/xdjeyf7u/
Benzinga Newsdesk

Mon Sep 21, 2026

Novo shares are trading lower after management comments at the company's Capital Markets Day may have failed to address investor concerns over its strategy for growth in its semaglutide and other therapy portfolios.

Morgan Stanley

Fri Sep 11, 13:38

sell

downgrade

Advanced Data Unlock

RGTI $14.14 USD

MPC $463.66 USD

NBIS $219.70 USD

XOM $168.54 USD

MSTR $151.40 USD

PLTR $198.74 USD

QQQ $747.70 USD